BioMarin guides ~$3.2B FY2025 revenue; plans $850M notes + $2.8B loans for Amicus deal

BIOMARIN PHARMACEUTICAL INC

FY2025 preliminary total revenue ~$3.2B, including ~$920M from VOXZOGO; cash & investments ~$2.1B.
Launches $850M senior notes due 2034 and $2.8B in term loans ($2B Term Loan B + $800M Term Loan A) plus $600M revolver.
Proceeds escrowed; notes due Dec 2034 subject to special mandatory redemption at 100% if Amicus acquisition fails to close by Dec 19, 2026.
Acquisition of Amicus expected to close in Q2 2026, subject to Amicus stockholder vote and antitrust clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.